← Back to Search

Care Coordination for Cardiovascular Prevention in Psoriatic Disease (CP3 Trial)

N/A
Recruiting
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female aged 40-75
Be older than 18 years old
Must not have
Currently taking a prescription lipid lowering medication
Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to use a new program to help patients with psoriatic disease lower their risk of heart disease through better care.

Who is the study for?
This trial is for men and women aged 40-75 with psoriasis or psoriatic arthritis, who are currently under dermatology care. It's not open to those on prescription lipid-lowering meds, pregnant or planning pregnancy soon, or with a history of cardiovascular diseases like heart attack or stroke.
What is being tested?
The study is testing a new 'care coordinator' program designed to help patients with psoriatic disease reduce their risk of developing cardiovascular disease by following standard healthcare practices to manage risk factors.
What are the potential side effects?
Since the intervention involves standard care coordination rather than medication, direct side effects are not expected as in drug trials. However, changes in lifestyle or diet as part of the coordinated care may have individual health impacts.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on medication to lower my cholesterol.
Select...
I have a history of heart or blood vessel diseases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in LDL
Secondary study objectives
30% LDL reduction
50% LDL reduction
Addition of new medication
+18 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Care CoordinationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,084 Previous Clinical Trials
42,726,528 Total Patients Enrolled
National Psoriasis FoundationOTHER
11 Previous Clinical Trials
1,362 Total Patients Enrolled

Media Library

Care Coordination Clinical Trial Eligibility Overview. Trial Name: NCT05908240 — N/A
Cardiovascular Disease Research Study Groups: Care Coordination
Cardiovascular Disease Clinical Trial 2023: Care Coordination Highlights & Side Effects. Trial Name: NCT05908240 — N/A
Care Coordination 2023 Treatment Timeline for Medical Study. Trial Name: NCT05908240 — N/A
~160 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top